FDA Approves Rexulti for Agitation in Alzheimer’s
The D2 dopamine receptor agonist reduced agitation behaviors in Phase 3 trials of dementia due to AD.
6448 RESULTS
Sort By:
The D2 dopamine receptor agonist reduced agitation behaviors in Phase 3 trials of dementia due to AD.
Scientists celebrated LaDu's scientific and academic career at Chicago memorial.
Bound up in vesicles extracted from Alzheimer's brain, tau filaments adopt their characteristic back-to-back C-shape. A mystery molecule is involved in tying them down.
The public database includes information about the structure, polarity, and stability of both pathogenic and functional amyloid folds.
One study links early menopause to tangles in early AD, another finds a sex difference in the brain's stress response. Could hormones fuel women’s higher risk of dementia?
A deletion in the gene for a lysosomal ion channel popped out of a genomic analysis of LBD risk. So did rare structural variants in other FTD and ALS genes.
While memory problems plague some people with lingering COVID symptoms, researchers do not yet understand what is going wrong in their brains.
In sleep-deprived mice, TREM2 signaling activated microglia in a dysfunctional way, hobbling their endolysosomes and keeping them from digesting Aβ plaques.
The antibody slowed decline by 35 percent, met secondary endpoints, will likely be approved. Major question: How to avoid severe ARIA.
Scientists devised fresh approaches for curbing tau tangles that might better reach the protein inside cells, or target several pathologies at once.
Data from TRIAD cohort cast activated microglia, egged on by ApoE4, as harbingers of tau pathology and neurodegeneration. Data from BioFinder hint that other microglia restrain these processes.
In Alzheimer’s, Parkinson’s, and Lewy body dementia, phospholipid and cholesterol homeostasis are disrupted early on. Scientists are bringing new methods to bear on the problem.
Safety and cerebrospinal fluid tau data from the six-month Phase 1 trial are now published.
cGAS and STING initiate a type I interferon response, which weakens neurons’ resilience to tau pathology.
The antisense oligonucleotide targets extremely rare variants of the superoxide dismutase 1 gene.